Invasive aspergillosis (IA) is among the major causes of fatalities among critically immunocompromised patients (Challa, 2018). According to Challa (2018), this condition results from an opportunistic infection of Aspergillus that exists in airborne pathogenic mould. Nonetheless, diagnostic delays form a substantial limitation to the fruitful treatment. Its diagnostic approaches necessitate the utilization of culture and histology, which are the basis of diagnosing IA. This study creates an IA care plan using the symptoms of a 49-year-old patient.
Symptoms
Generally, invasive aspergillosis befalls patients with immunosuppression or persistent neutropenia (Challa, 2018). Its symptoms are cough, fever, hemoptysis, chest pain, dyspnea, and pleuric. Furthermore, IA patients could be tachypneic and have quickly progressive hypoxemia. This disease has numerous risk factors. Examples include a transfer of bone marrow that happens early with resilient neutropenia prior to engraftment. This resilience can also remain later in high-dose corticosteroid therapy for the graft-against-host condition. Lastly, IA has a bimodal spreading, and extra symptoms can advance when the infection spreads beyond the lungs to different body parts (Jenks & Hoenigl, 2018).
Diagnosis
Diagnosis of patients’ IA is fundamental for successful treatment (Jenks & Hoenigl, 2018). This process necessitates depicting the organism at the tissue level by visualizing the typical fungi employing a silver stain called Gomori methenamine. According to Jenks and Hoenigl (2018), the positive culture outcome from bronchoalveolar lavage fluid, sputum or needle biopsy is also a useful diagnostic test. The subjective and objective information presented in this case scenario confirms that the patient grapples with Invasive Aspergillosis. The individual suffered fever and chest pain that are both main diagnostic measures for IA. Furthermore, the 49-year old individual has chest pain associated with coughing.
Genes that May be Linked with the Development of Invasive Aspergillosis
A remarkable fraction of IA’s vulnerability markers are directly found at the gene level (Lupiañez et al., 2016). Alternatively, the markers are indirectly involved in activating the signalling pathway of the nuclear factor-kappa B (NFκB) (Lupiañez et al., 2016). A rising number of investigations prove that host genetic polymorphisms near or within the immune-based genes may significantly contribute to determining the likelihood of suffering an IA infection. Precisely, solitary nucleotide polymorphisms (SNPs) inside, C-type lectins, tumour necrosis factors and toll-like receptors that are all pathogen acknowledgement receptors that typically end in the initiation of NFκB trail, can upsurge the possibility of patients suffering IA. Studies by Lupiañez et al. (2016) determined that the existence of collective genetic polymorphisms in IRF4, NFκB1, NFκB2, Rel, RelA and RelB genes could substantially stimulate the possibility of evolving IA, particularly for the high-risk population (Lupiañez et al., 2016).
Immunosuppression Process and its Effect on Body Systems
Immunosuppression denotes a practice of purposely directing drugs that include corticosteroids, azathioprine cyclosporine or FK506 to slow down the immune response among patients undertaking bone marrow or organ transplants (Jenks & Hoenigl, 2018). According to Mangani, Weller and Roth (2017), during immunosuppression, Glioma cells trigger an immunosuppressive process that weakens the effector cells and reduces the efficacy of healing approaches that strive to reinforce immune reaction against tumours. In other instances, immunosuppression could occur as an antagonistic response to the cure of other health disorders. Ideally, immunosuppression significantly affects a patient’s immune system since it lessens the immune system efficacy or activation to counter infections. Consequently, the immune system wanes, making the patient defenceless to infectious ailments (Jenks & Hoenigl, 2018).
In conclusion, Invasive aspergillosis is common in immunosuppressed persons and is linked with significant morbidity and mortality. As such, cognition about its pathology and pathogenesis simplifies diagnosis and therapy to reduce its adverse impacts on public health.
References
Challa, S. (2018). Pathogenesis and pathology of invasive aspergillosis. Current Fungal Infection Reports, 12(1), 23-32.
Jenks, J. D., & Hoenigl, M. (2018). Treatment of aspergillosis. Journal of Fungi, 4(3), 98.
Lupiañez, C. B., Villaescusa, M. T., Carvalho, A., Springer, J., Lackner, M., Sánchez-Maldonado, J. M., & PCRAGA Study Group. (2016). Common genetic polymorphisms within NFκB-related genes and the risk of developing invasive aspergillosis. Frontiers in microbiology, 7, 1243.
Mangani, D., Weller, M., & Roth, P. (2017). The network of immunosuppressive pathways in glioblastoma. Biochemical pharmacology, 130, 1-9.
